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During the last decade, many studies have demonstrated the role of CMV specific T-cell
immune response on controlling CMV replication and dissemination. In fact, it is well
established that transplanted patients lacking CMV-specific T-cell immunity have an
increased occurrence of CMV replication episodes and CMV-related complications. In
this context, the use of adoptive transfer of CMV-specific T-cells has been widely
investigated and applied to Hematopoietic Stem Cell Transplant patients and may be
useful as a therapeutic alternative, to reconstitute the CMV specific T-cell response and to
control CMV viremia in patients receiving a transplantation. However, only few authors
have explored the use of T-cell adoptive transfer in SOT recipients. We propose a novel
review in which we provide an overview of the impact of using CMV-specific T-cell
adoptive transfer on the control of CMV infection in SOT recipients, the different
approaches to stimulate, isolate and expand CMV-specific T-cells developed over the
years and a discussion of the possible use of CMV adoptive cellular therapy in this SOT
population. Given the timeliness and importance of this topic, we believe that such an
analysis will provide important insights into CMV infection and its treatment/prevention.
Keywords: cytomegalovirus, CMV-specific immune response, T-cell adoptive transfer, CMV treatment,
cellular therapyINTRODUCTION
Viral infection, including cytomegalovirus (CMV), BK virus and Epstein-Barr virus, remains a
major cause of morbidity and mortality in immunocompromised individuals (1–5). While in
immunocompetent individuals latent CMV infection is controlled by the immune system (6), in
transplant recipients, both hematopoietic stem cell (HSCT) and solid organ transplantation (SOT),
CMV infection is one of the main infectious complications. CMV seropositive allogeneic HSCT
patients presents the highest risk of recurrent infections, followed by CMV seronegative SOT
recipients that receive a graft from a seropositive donor (R-/D+), HIV patients, and patients who
have received T-cell depletion therapies (alemtuzumab, antithymocyte globulin, or post-transplant
cyclophosphamide) (6, 7). The incidence of CMV reactivation/reinfection in SOT is 16–56% (8–12),
with a median value of 30%, while in HSCT has been reported to be 30–70%, with a median value oforg April 2021 | Volume 12 | Article 6571441
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causing viral syndrome with clinical manifestations such as
gastroenteritis, pneumonitis, hepatitis, uveitis, retinitis, encephalitis
and graft rejection, CMV infection also cause indirect effects related
with increased incidence of graft rejection and opportunistic
infections or decreased recipient survival (16–18).
Cell mediated immune response is considered the most
important arm of the immune system against CMV infection
with increasing evidences demonstrating a role of CMV-specific
T-cells in protecting from infection, which can contribute to
improve clinical care after transplantation (19–27).
A few authors have suggested the importance of monitoring
patient’s CMV-specific immunity using standardized tools for
individualizing the risk of CMV infection after transplantation
(21, 28–31). Thus, using both immunological and virological
patient monitoring may provide a wider knowledge of patients’
clinical situation that may facilitate clinical decisions during
follow-up of SOT recipients (32).
Although the antiviral drugs to treat CMV infection have
highly improved during the years, there are still some issues
associated with the use of the available antivirals (ganciclovir,
foscarnet, cidofovir and more recently letermovir) such as
undesirable side effects (nephrotoxicity) and selection of
resistance mutations in addition to the high cost. Consequently,
strong efforts have been made to search for new therapeutic
approaches (33).
In this context, the use of cellular therapy may be useful to
reconstitute the CMV specific T-cell response and to control
CMV viremia in SOT recipients. Here we provide a synthesis of
recent data regarding the impact of using CMV-specific T-cell
adoptive transfer on the control of CMV infection in SOT
recipients, the different approaches to stimulate, isolate and
expand CMV-specific T-cells developed over the years and a
discussion of the possible use of CMV adoptive cellular therapy
in these patients.USE OF ADOPTIVE TRANSFER OF CMV-
SPECIFIC T-CELLS IN THE CONTEXT OF
SOLID ORGAN TRANSPLANTATION
The use of CMV-specific T-cell adoptive transfer is currently
being evaluated for clinical application, with promising results as
a treatment for CMV infection and disease in ulcerative enteritis
in primary immunodeficiency (34) or in pediatric retinitis caused
by CMV (35).
In the context of transplantation, CMV-specific T-cell
transfer has been widely investigated and applied to
Hematopoietic Stem Cell Transplant (HSCT) patients, both
prophylactically, to reconstitute protective antiviral immunity,
and as a treatment in patients with refractory CMV infection
(36–38). In contrast, in SOT recipients it has been less
investigated probably due to the T-cell response attenuation
produced by the administration of the immunosuppressive
therapy. In addition, SOT recipients may not tolerate donor-Frontiers in Immunology | www.frontiersin.org 2derived cytolytic T lymphocytes (CTLs) due to the activation of
cytokine-mediated stimulation of the alloreactive T-cells causing
direct alloimmune injury (39, 40).
Few authors have explored the use of T-cell adoptive transfer
in SOT recipients during the last decade (Table 1). In 2009,
Brestrich et al. (41) performed a study in a lung transplanted
recipient with a severe and persistent CMV pneumonia resistant
to ganciclovir and foscarnet. Patient´s peripheral blood
mononuclear cells (PBMCs) were stimulated with overlapping
peptide pools covering the whole protein IE-1 and pp65 and
CMV-specific INF-g positive cells were subsequently selected
and infused. The patient was treated with two infusions of 1 ×
107/m2 CMV‐specific T-cells. After the first infusion, the patient
developed an overall improvement, with a decrease of the viral
load and pneumonia symptoms and an increase of the CMV-
specific T-cell levels. Four weeks after the first infusion, a second
infusion was administered due to a worsening of the disease,
testing positive for CMV. However, the patient died due to graft
failure with a negative biopsy for CMV antigen (41).
Since then, a number of authors have explored the potential of
T-cell adoptive transfer as a therapy in SOT recipients (42). A
renal transplant recipient (D+/R-) with refractory CMV infection
received partially HLA-compatible (at three of six HLA loci A, B
and DRB1) CMV-specific T-cells at a dose of 1.6 × 107 T-cells/m2,
successfully generated from a third donor. Nineteen days
following the infusion, a fifty fold decreased of the CMV DNA
viral load was observed and plasma exchange was ceased due to
resolution of hematological features of thrombotic
microangiopathy (platelets 269 × 109/L, LDH 369 IU/L, no red
cell fragments on blood film). Patients was discharged from
hospital four weeks after the infusion (43). The authors
highlighted the effective application of CMV-specific CTLs from
third donors, suggesting that creating donor cell-banks could be
useful as a therapeutic alternative in SOT recipients (43–45). In a
later study, the same group successfully expanded autologous
CMV-specific T-cells from a seronegative recipient that received a
seropositive lung allograft and that developed a CMV disease due
to ganciclovir resistant CMV infection (46). CMV-specific T-cells
were isolated and stimulated with autologous PBMCs coated with
HLA class I-restricted CMV peptide epitopes, based on patient´s
HLA class I typing. The in vitro expanded T-cells showed an
increase in HLA epitopes (A1, B7 and B35) and in the proportion
of IFN-g+ CD107a+ cells that indicates the granule-dependent
(perforin/granzyme) pathway of cytotoxic CD8+ T-cells. The
patient received four infusions of 3 × 107 autologous T-cells.
After the infusion of the in vitro expanded T-cells no adverse
events occurred, the CMV viral load became undetectable, the
patient’s usual immunosuppression regime was resumed, hepatic
and bone marrow function remained normal with no evidence of
acute rejection. These results indicated that adoptive therapy
can contribute to immune control of CMV infection (46).
Pierucci et al. (47) employed autologous T-cell transfer in a
seronegative lung transplant recipient with a ganciclovir and
foscarnet resistant CMV infection, who also developed
cidofovir-related nephrotoxicity. Cells were obtained from
patient´s peripheral blood and expanded using epitopes ofApril 2021 | Volume 12 | Article 657144
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Around 42% of the obtained CD8+ T-cells were CMV-specific
and T-cells were restricted to three HLA Class I alleles: HLA-A1,
HLA-B7 and HLA-B8. The patient received 2 infusions (1.9 x 107
T cells/infusion) 2 weeks apart, with no side effects and with low
CMV titers during two months after which a relapse of the viral
load occurred. The patient received a third infusion (22.2 x 106
T-cells) showing some therapeutic benefit, with further significant
reduction in CMV titers, which was maintained for 2 months.
The patient did not have any documented rejection or acute
change in lung function after the T-cell infusions. However, the
patient died due to clinical complications unrelated to CMV
infection (47).
The most ambitious study carried out to date was performed in
a cohort of 21 SOT recipients (13 kidney, 8 lung and 1 heart) who
developed recurrent ganciclovir resistant CMV infections. Thirteen
of these patients (8 D+/R-, 3 D+/R+ and 2 D-/R-) were subjected to
T-cell (ranging from 22.2-245 × 106 T-cells) adoptive transfer
receiving amaximum of 6 doses one of which discontinued therapy
after a single dose. Adverse events attributable to T-cell infusion
were grade 1 or 2 (fatigue and malaise) with no adverse events
associated with a change in the graft status. Eleven of the 13 showed
objective improvement in their symptoms including a reduction
(with a median drop of 1.2 × 103 CMV copies/mL) or resolution of
CMV reactivation and resolution of CMV disease symptoms. In
addition, the use of antiviral drug therapy was either completely
stopped (in 5 of 11 patients) or significantly reduced (in 6 of
11patients). Evidences of immunological reconstitution was
associated with control of viremia (48).
Based on these promising results, several clinical studies are
currently been conducted: (i) A clinical trial (NCT03665675)
including 20 patients, both HSCT recipients and SOT recipients
is been conducted, to study the effect of transferring allogeneic
CMV-specific T lymphocytes on CMV infection or reactivation.
The first results will be available at the end of 2021. (ii) A clinical
trial (NCT02779439) with 25 patients enrolled, to elucidate the
biological efficacy of therapeutically administered most closely
HLA-matched third-party donor-derived specific cytotoxic T
lymphocytes (CTLs) targeting CMV, following allogeneic blood
or marrow stem cell or SOT. (iii) A clinical trial (NCT04364178)
including 25 patients assessing whether partially matched, ≥2/6
HLA-matched, viral specific T-cells have efficacy against CMV in
subjects who have previously received any type of allogeneic
HSCT or SOT. (iv) A clinical trial (NCT03266640) with 20
participants investigating the therapeutic role of CMV CTLs in
children, adolescents and young adults (CAYA) with refractory
CMV infection post allogeneic HSCT or SOT.
Together these results suggest that, although there is still
space for improvement, the use of CMV-specific T-cell adoptive
transfer is promising in SOT recipients with limited options for
CMV-infection treatment.CELLULAR THERAPIES AVAILABLE
During the last years a better understanding of the CMV-specific
T-cell immunology such as the conserved T-cell epitopes (49),Frontiers in Immunology | www.frontiersin.org 3has led to the improvement of the methods for ex vivo T-cell
culture (50). In addition, rapid tests to evaluate the effector
function of the CMV-specific T-cells have become available
(51, 52). In this section, we describe the features of the
methodologies available to generate CMV specific T-cells,
which are summarized in Figure 1 and Table 2.
T-Cell Expansion
To successfully generate and expand CMV-specific T-cells, it is
crucial to define the most immunogenic epitopes used by the
antigen presenting cells (APC) to promote the activation and
proliferation of peptide-specific T-cells (53). A large number of
antigens expressed at different stages during viral replication
participate in the activation of both CMV-specific CD8+ and
CD4+ T-cells, known to mediate the immune response against
the virus (50). IE-1 and pp65 proteins are two of the most
immunodominant CMV antigens and have been widely used to
stimulate the CMV-specific immune response (50, 54–56).
Different approaches have been carried out for in vivo
expansion and generation of CMV-specific T-cells (57). In the
initial studies, CMV-specific CD8+ T-cell clones were generated
by stimulating donor peripheral blood mononuclear cells
(PBMC) with CMV-infected fibroblasts (23). However, this
approach was discontinued because of the risk of producing
infection in patients. Later, CMV lysates or pp65-NLV peptide
were used to stimulate CMV-specific T-cells (58–60). Using the
pp65-NLV peptide only stimulated adoptive immunity against a
single viral epitope (50) and its application may be limited for
HLA-A2 patients/donors (60). To overcome this problem, “poly-
specific” products targeting multiple antigens were generated by
incubating allogeneic T-cells in vitro with clusters of 15-mer
peptides spanning the entire pp65 antigen to generate CMV-
specific oligoclonal T-cells (61). Adoptive transfer of the
oligoclonal T-cells were able to eliminate viremia, and infused
cells persisted for up to two years (61, 62).
The improvement of the methodology for ex vivo expansion
has reduced the presence of alloreactive or naive T-cells in the final
product (63). In addition, T-cell ex vivo stimulation and expansion
requires a small blood volume to establish the T-cell culture,
making possible the generation of CMV-specific T-cells from low
levels of circulating T-cells and naive donor sources (51).
Direct Selection Using Specific
Peptide–MHC (pMHC)
Using pMHC multimers allows to isolate T-cells based on the T-
cells receptor (TCR) ability to bind a complex mixture of
peptide-loaded recombinant HLA molecules (53). Since this
method is restricted by HLA type, a previous knowledge about
the immunodominance of the epitopes is necessary. HLA-
peptide tetramers from pp65 and IE-1 proteins have been
previously used to select CD8+ T-cells that were further
isolated using magnetic beads (64).
This method allows to reduce the time and improve the
quality of the final product, minimizing alloreactivity (57).
However, the main disadvantages of this technique are related
with the limitation of the method to isolate only CD8+ or CD4
T-cell populations, and the irreversibility of the binding that canApril 2021 | Volume 12 | Article 657144
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alterations of the purified T-cell population (such as TCR
internalization, activation, overstimulation and cell death)
(65–67). It has been shown that pMHC multimer binding
interferes with the functional status of epitope-specific T-cell
population in vivo, causing epitope-specific tolerance in a dose-
dependent manner (68, 69). This intrinsic characteristic of
pMHC multimer binding substantially limits the clinical
application of this technology.
This issue has been further solved with the development of
the Streptamer technology in which the binding of the HLA
peptide and the antigen-specific TCR is reversed, by competing
with a molecule that causes the Streptamer to monomerize,
causing no alteration of the phenotype or the functional status
of the T-cells (70–72). However, the selected T-cells are limited
by the HLA restriction imposed by the Streptamer, and this may
be a limitation for CD8+ T-cells survival when CD4+ T-cells are
absent (73). Some authors have used this new technology to
isolate CD8+ T-cells from CMV seropositive donors,
demonstrating both immune reconstitution, as well as antiviral
safety and efficacy after HSCT (74, 75). The results obtained with
this technology are promising however, further studies are
necessary to demonstrate efficacy in SOT recipients.
In the context of SOT, p-MHCmultimers has been previously
used using autologous T-cells harvested from lifelongFrontiers in Immunology | www.frontiersin.org 4immunosuppressed patients (while healthy donors were used
in HSCT). In these patients, deficiencies in T-cell differentiation,
longevity, as well as the use of immunosuppressive regimen can
affect to long-term survival of the transplanted cells limiting its
use for adoptive therapy (76). The associated challenges of this
method could be minimized by using partially HLA-matched
CMV-specific T-cells obtained from a third party donor (43).
This approach was shown to be safe to treat CMV infection in
SOT patients, however, more research is needed (43).
Direct Selection Using Cytokine Capture
System (CCS)
CMV-specific T-cells can also be selected using IFN-g cytokine
capture system (CCS), a rapid assay that allows to select and enrich
CD8+ and CD4+ INF-g secreting T-cells that have been previously
stimulated using viral antigens (77). This strategy allows T-cell
selection that in contrast with pMHC has no HLA restriction and as
an additional benefit, stimulating and capturing a polyclonal
population of CD4+ and/or CD8+ T-cells depending on the
antigen used for stimulation, not achieved using the Streptamer
strategy. Different authors have successfully isolated functional
CMV-specific T-cells using this method. Two of these studies
stimulated donors PBMC using pp65 that were administrated to
patients after HSCT who were able to expand the CMV-specific T-
cells and reduced the CMV load in blood (78, 79). More recently,A B C
FIGURE 1 | Strategies for the generation of CMV-specific T-cells. (A) Ex vivo T-cell expansion requires the in vitro stimulation and expansion of T-cells using APCs
presenting viral peptides or proteins. (B) Direct selection employs virus-derived peptide specific multimers in the setting of a HLA class-I molecule, viral antigen T-cell
stimulation followed by cytokine expressing T-cell selection using antibody coated immunomagnetic beads or activation marker selection based on the detection of
specific surface molecules that are selectively expressed or strongly up-regulated after T-cell activation. (C) Genetic manipulation requires gene transfer of high affinity
CMV-specific T-cell receptors (TCR) or chimeric-antigen receptors (CAR) to change specificity of T-cells to CMV antigens. This figure was created using BioRender.com.April 2021 | Volume 12 | Article 657144
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Frontiers in Immunology | www.frontiersin.org 5Kim et al. (80) used the automated CliniMACS Prodigy platform to
generate pp65-specific CTL that exhibited functional activity,
including efficient proliferation, sustained antigen-specific IFN-g
secretion, and cytotoxicity against pp65-pulsed target T-cells.
Although little clinical experience is available, this approach has
the potential to be applicable to any type of patients with a clinical
emergency due to CMV-related diseases including SOT recipients
(80, 81).
Other selection strategy is to isolate and enrich activated viral-
specific T-cells after antigen stimulation based on the detection of
specific surface molecules that are selectively expressed or strongly
up-regulated after T-cell activation, such as CD25, CD69, CD137
and CD154 (82–84). In this sense, several publications have shown
results using CD137 as a specific activation marker due to its
predominant expression on T lymphocytes after activation,
including CD8+ and CD4+ cells (85, 86). This approach allows
simultaneous targeting of antiviral T-helper and effector cells.
Other data showed the feasibility of isolating CMV-specific T-cells
from PBMCs through the use of CD25 and CD154 activation
marker expression (82, 87). However, as both markers are
predominantly expressed in CD4+ T-cells, these strategies do
not allow the enrichment of CD8+ cytotoxic T-cells.
T-Cell Generation Using Activation Marker
and Engineered T-Cells (CAR, TCR)
Other interesting strategies based on the successful performance
for cancer treatment (88–90) is the gene modification of patient’s
lymphocytes with tumor-specific T-cell receptors (TCRs) or
chimeric antigen receptors (CAR). The generation of
autologous CAR T-cells which has also been explored as
immunotherapy against CMV (91, 92, 93) enables antigen
recognition in a MHC independent manner and can be
designed to specifically target conserved and essential epitopes
of the selected antigen (94), overcoming pathogen escape
mechanisms. In a nutshell, CAR consists of a defined antigen-
binding domain represented by a single-chain fragment variable
(scFv) antibody, an extracellular spacer region, a transmembrane
domain, and an intracellular domain that triggers T-cell
activation, mainly by the T-cell receptor signaling domain
CD3z (94). Several groups have recently generated gB-targeted
CAR T-cells using scFvs derived from gB-specific NAb antibody
(SM5-1) fused to CARs with 4-1BB (BBL) or CD28 (28S)
costimulatory domains and subcloned into retroviral vectors
(95, 96). In a recent study, CD4+ and CD8+ T-cells obtained
from blood or cord blood of CMV-seronegative donors were
transduced showing efficacy in preclinical models (96). Further
clinical studies will be necessary to demonstrate in vivo efficacy.
The other TCR strategy uses heterodimers integrated by alpha
and beta peptide chains to recognize specific polypeptide
fragments presented by MHC complexes. While CAR-T-cell
therapy identifies exclusively antigens located in the cell
surface, TCR can also recognize intracellular antigenic
fragments presented by MHC molecules (97). However, TCR
T-cell therapy is restricted to MHC presentation, which
represents a limitation of the strategy. The main goal of TCR
T-cells is to modify the TCR binding to the pathogen antigens.
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problem, modifications of the TCR using genetic engineering
technology has been able to enhance the specificity and affinity of
the recognition of the antigens by T-cells (98).
Cell Therapy Limitations and Alternatives
in SOT Patients
The intensity and long-term immunosuppression requirement to
prevent allograft rejection pre-disposes SOT recipients to a wide
range of viral complications (1). In addition, antiviral treatment can
generate side effects such as nephrotoxicity (99), and the selection of
drug-resistantmutantCMVstrains (100), limiting treatmentcapability
in SOT recipients. Based on these limitations, cell therapy may be an
appropriate and effective alternative antiviral treatment. However, as
pointedoutpreviously,deficiencies inT-celldifferentiationand lifelong
immunosuppression can affect to long-term survival of the transfused
cells, interfering in the antiviral functionality and limiting its use for
adoptive therapy in SOT recipients (76). Here, we analyze the
alternatives available to overcome these limitations.
Different authors have demonstrated that in vitro generated
CMV -specific CTL are highly sensitive to immunosuppressive
drugs (such as cyclosporin A and FK506) impairing the
production of effector cytokines (101, 102). A possible solution in
order to overcome this problem, is to genetically modify the in vitro
generated CTL to confer resistance to these drugs (103, 104).
Alternatively, decreasing patient´s immunosuppression during a
period post-infusion may allow the expansion and functionality
of the CMV-specific T-cells. As an example, Macesic et al. used
third-party T-cells to infuse a kidney transplant patient who had
ganciclovir resistant persistent CMV viremia, and decreased the
levels of immunosuppressive drugs. A significant decrease of the
patient CMVDNAviral load, from>5x106 copies to 682 copies/mL,
was observed within 4 months after transfusion and remained
controlled up to 1 year, leading to clearance of the infection (43).
These results suggested that the use of third-party CMV-specific T-
cells could be used in patients that admit a reduction of theFrontiers in Immunology | www.frontiersin.org 6immunosuppression regimen without compromising the
allograft stability.
Another limitation is associated with deficiencies of T-cell
differentiation in SOT recipients receiving immunosuppression.
Most of the studies have used the viral antigens UL123 (IE1) and
UL83 (pp65), known to promote a strong T-cellular response, for
T-cell ex vivo stimulation to generate CMV-specific oligoclonal
T-cells. Few studies have provided information regarding the cell
mediated response to other viral multiple antigens in addition to
IE1 and pp65 (54, 105–107). Thus, efforts should be made to
promote the generation of CD8+ and CD4+ T-cells displaying
multiple polyfunctional effector functions that may be more
effective in controlling CMV infection (50, 54–56).
As previously mentioned infusion of donor derive T-cells
from donors may also transfer alloreactive T cells in numbers
sufficient that could trigger episodes of rejection, particularly if
the donor and the host differ in one or more HLA alleles, due to
sensitization to specific non-self HLA alleles present on the
donor T-cells. A way of assessing this issue is to extensive
culturing T cells or even establishing T-cell clones to eradicate
alloreactive T cells but may also result in replicative senescence of
the ex vivo-manipulated virus-specific T cells (108).
The creation of third-party cell banks as well as third party
donor registries has emerged as a new possibility of treatment
that employs T-cells derived from partially HLA-matched third-
party donors (109). The use of this method allows to achieve a
rapid “off the shelf” product that could be used in a broader range
of patients. Furthermore, it offers the potential advantage of
targeting multiple viral epitopes rather than a monospecific
approach, potentially increasing the antiviral effect (109). Over
the past years third party donor T-cell banks have been
established. Such banks permit selection of T-cells on the basis
of HLA allele phenotype, viral specificity and HLA restriction,
which may provide distinct advantages, particularly in the
treatment of HLA non-identical recipients. Although it is still
under study, the obtained results to date are highly promising.TABLE 2 | Characteristics of the T-cell therapies available.
Method System Advantages Disadvantages
Ex vivo
expansion
No restricted by HLA type; small blood volume required; naïve donor can
be used; generation of polyclonal T-cells





No needed extensive ex vivo manipulation and undergo rapid expansion
in vivo
Restricted by HLA type and streptamer; seropositive donors
required; high frequency of specific T-cells needed; select for a
limited repertoire of CD8+ cells
Cytoquine
capture
No needed extensive ex vivo manipulation and undergo rapid expansion
in vivo; not restricted by HLA type; isolation of polyclonal CD4+ and CD8+
cells
Requires seropositive donors; large blood volumes needed
Activation
marker
Rapid detection and enrichment of T-cells; broader repertoire of antigen-
specific T-cells; Compatible with other assay formats; not restricted by
HLA; not needed previous information of immunodominant epitopes; no
specialized APC such as dendritic cells are needed
Time-consuming and difficulty to isolate and expand functional
cells; identification of novel T-cell epitopes often requires




CAR-T Recognize antigens in an HLA-independent manner; target conserved and
essential epitopes; infused to a broad range of patients irrespective of
HLA
Only surface antigens can be targeted; restricted by epitope;
expensive; Several toxicities
TCR-T Wider range of targets; high affinity for specific antigens through genetic
engineering; strong activation when a small amount of antigen is present;
use of natural T-cell signaling mechanisms
Expensive; time- and labor-consuming; MHC restricted and
depends on presentation by MHC molecules to recognize
targets and activate T cell function; risk of hybridization
(mismatch) between exogenous and endogenous chainsApril 2021 | Volume 12 | Article 657144
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PERSPECTIVES
CMV is a major cause of severe complications in SOT recipients
such as graft loss especially in patients that develop CMV
infection with antiviral refractory CMV strains (110, 111). The
period early after the transplant is considered critical due to the
high risk of infections associated with a high incidence of CMV
(42). The role of CMV-specific T-cell immune reconstitution
after SOT have demonstrated several benefits, including lower
risk of CMV infection and graft rejection. Thus, the development
and improvement of new CMV-specific T-cell transfer based
therapies could be a useful to adjust the therapeutic interventions
(112–114). However, despite the increasing interest on adoptive
CMV specific T-cell transfer, most of the information available
comes from studies in HSCT recipients (23, 53, 115). Only few
reports including a small number of SOT recipients have used T-
cell adoptive immunotherapy as a treatment of CMV infection or
disease (41, 43, 46–48). These studies enrolled SOT recipients
that previously failed to conventional treatment, with low
survival rate. Although promising results were obtained,
further development have been limited due to difficulties of T-
cell expansion in SOT that are receiving immunosuppressive
regimens, and the risk of graft rejection after T-cell
administration. One possible approach to overcome these
limitations is generating ready to use third-party CMV-specific
T-cell banks to ensure the availability of well characterized the
T-cell products (57, 116). In addition, better results should be
obtained using T-cell adoptive immunotherapy in SOT
recipients that had optimal clinical outcomes. Results from the
ongoing clinical trial analyzing the safety and feasibility of
administering CMV specific- CTLs from haploidentical donors
in transplant patients would be of importance to implement
T-cell adoptive therapy in SOT recipients.CONCLUSIONS
Recent studies have significantly increased our knowledge about
the protective role of CMV-specific T-cell immune response
against CMV infection and disease. And thus the use of T-cell
adoptive therapy may help to restore the CMV-specificFrontiers in Immunology | www.frontiersin.org 7immunity for preventing CMV infection in addition to serve as
a treatment for CMV infections in SOT individuals who do not
respond to conventional therapies, such as patients infected with
antiviral resistant strains with no alternative treatment available.
Recent findings regarding the development of new techniques to
select, isolate and enrich functional CMV-specific T-cells and the
possible generation of third party donor cell banks may help to
use CMV-specific adoptive transfer as an alternative therapy for
SOT recipients. However, further work is clearly needed in order
to fully understand and assess the clinical utility of these
techniques in SOT recipients.AUTHOR CONTRIBUTIONS
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21. López-Oliva MO, Martinez V, Buitrago Á, Jiménez C, Rivas B, Escuin F,
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